Executive Committee

Emma is a Consultant Pharmacist at the Royal Marsden Hospital in London. She has an MSc in Clinical Oncology and is an Independent Prescriber. Emma is currently Joint Chair of BOPA as well as Chair of the ISOPP Biosimilars Taskforce and a reviewer for the Journal of Oncology Pharmacy Practice. She was awarded the BOPA/PRUK research award in 2018 for a study investigating drug interactions between enzalutamide and DOACs. Emma is a visiting lecturer at the University of Brighton and enjoys teaching on the BOPA Intro to Oncology Study Day . Her special interests include renal cancer, drug interactions, non-medical prescribing (and canoeing!).

Seonaid McLachlan is Principal Pharmacist for Cancer Services in NHS Ayrshire & Arran. Seonaid is currently Joint Chair of BOPA and she is also a member of the Scottish Oncology Pharmacy Practice Group (SOPPG) and is the formal link between BOPA and SOPPG. As well as working for many years as a cancer care pharmacist, Seonaid has previously worked with the Scottish Medicines Consortium undertaking horizon scanning for cancer medicines in Scotland and was the pharmacy lead on the recent West of Scotland Strategic Review of Cancer Services. Her interests include service planning and redesign, particularly focusing on role development for pharmacists and technicians working in cancer services.

Netty is an experienced oncology pharmacist and has worked for over 15 years in this sector. She has a vast range of experience including lead oncology and haemato-oncology pharmacist within an NHS Trust, a lead role within an NHS cancer network, and project management roles for the implementation of SACT electronic prescribing both in the NHS and the independent sector. During these 15 years Netty has been an active member of BOPA and her current role within the executive committee is the BOPA secretary and Co-Chair of the Digital Subcommittee.

Netty also chairs the Independent Sector Oncology Pharmacy Group and is a member of the Independent Sector Cancer Network and UK Chemotherapy Forum where she represents BOPA. She is passionate about improving cancer care within the independent sector and improving safety for patients and staff with the use of digital media.

Professor Rob Duncombe. Director of Pharmacy at The Christie NHS Foundation Trust in Manchester. The Christie is one of the largest cancer centres in Europe treating patients from across the UK. The hospital recently opened the first NHS proton beam centres in the UK, and is one of the first hospitals to offer CAR T therapy to patients. Professor Duncombe has a particular interest in medicines optimisation in cancer drugs, identifying ways to achieve the best value from the use of these medicines. In recent years Prof Duncombe has been at the forefront of delivering dose-banded chemotherapy in the UK and the introduction of biosimilar medicines in cancer.

Rich is a Regional Programmes Manager at Roche Products Limited. This role is non-promotional focused on NHS regional engagement and collaboration.

Rich previously worked in the NHS, his experiences include 10 years of working in the specialist areas of Haematology, Oncology and Aseptic services at The Clatterbridge Cancer Centre and Wirral University Teaching Hospital.

Olga is a senior haemato-oncology pharmacist. She is a qualified independent prescriber and was involved in the first pharmacist-led haematology MPD clinic at Newcastle Hospitals NHS Foundation Trust. She has a passion for providing education and training whilst promoting the value of the role of pharmacists in the healthcare system. She is now working at St James Hospital in Dublin.

Susanna Daniels has recently moved to the charity sector as a Project Manager of Melanoma Focus. The charity focuses on commissioning innovative research whilst providing high quality information to patients and healthcare professionals alike. Some of her projects include setting up a melanoma trial database for Health Care Professionals and patients, updating the patient support guide on melanoma and supporting the next biannual conference.

Prior to this, Susanna worked for over 3 years at MSD on pembrolizumab (melanoma and lung cancer) and a trastuzumab biosimilar. Activities involved operationalising the NSCLC EAMS scheme, running advisory boards and training.

All of Susanna’s previous experience is within the NHS in oncology. Her most recent role was as the Lead Cancer Services Pharmacist at UCLH (13 years). She is most proud of creating the renal and hepatic guidelines to support SACT dosing and introducing backpacks to ambulatory care to allow various patient groups have their treatment in the ambulatory setting, thus providing patients with greater autonomy and also freeing up much needed capacity.

Islam is the Lead Lung Cancer and Clinical Commissioning Support Pharmacist at the Royal Marsden NHS Foundation Trust. He has a passion for clinical leadership, interdisciplinary learning and research.

Emma is a clinical pharmacist who is new to oncology, currently working at The Newcastle Hospitals NHS Foundation Trust. She is interested in targeted cancer treatment and genomic medicine.

Fiona is the Cell therapy project lead at Kite Pharma. Interests include blood cancers and pharmacy practice research. She use to be a DJ; now she's a dog person.

Bryn has over 10 years experience working in oncology as a clinical pharmacist. He is a qualified independent prescriber with a special interest in prostate cancer. He has set up and delivered pharmacist prescribing service at the Royal Marsden Hospital. He is a current member of the BOPA executive committee and past Chair of the E&T subcommittee. He has recently joined Maggie's Cancer Centres where he is heading up the new centre at the Royal Marsden.

Pinkie is currently undertaking a PhD at University College London funded through the NIHR academy. Her research aims to determine the optimal blood testing validity periods for chemotherapy patients using risk modelling techniques. Her substantive role at UCLH is Lead Pharmacist for Applied Health research, a role that focuses on translational type 2 research. She has held various roles within cancer including developing new clinic pharmacy services at UCLH and Lead Pharmacist for London Cancer. She is a member of the UK Chemotherapy board as a BOPA representative , Joint Chair of The Chemotherapy Expert Reference group in London Cancer and a member of the Heath Foundation Q Community.

Steve Williamson is NHS England’s National Lead Cancer pharmacist. In this role Steve is part of the Cancer Drug Fund Team who are responsible for new cancer medicine implementation in England. Steve supports the Chemotherapy Clinical Reference Group (CRG) working alongside NHS England’s Lead Cancer Clinician. Steve was formally a Consultant Cancer Pharmacist at Northumbria Healthcare and was Chair of the British Oncology Pharmacy Association from 2017 to March 2019 authoring many of their Guidelines and National standards. Steve teaches on the Oncology MSc degree course at Newcastle University and has published and undertaken research on various topics on cancer medicines and chemotherapy service delivery.